Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Want to cut your energy bills? Here’s how five experts are doing it 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SEATTLE, March 06, 2017 -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 29th Annual ROTH Conference on Wednesday, March 15, 2017 at 10:30 AM PT at the Ritz Carlton, Laguna Niguel, California.
A live audio webcast of the presentation can be accessed at www.aptevotherapeutics.com under the ‘Investors’ section of the website, under ‘Events.’ An audio reply of the webcast will be available following the live webcast.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. Aptevo has four commercial products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.
Stacey Jurchison Senior Director, Investor Relations and Corporate Communications 206-859-6628 [email protected]
